Genmab | GEN - Selling And Administration Expenses



Genmab reported DKK144M in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.


Selling And Administration Expenses Change Date
Agios Pharmaceuticals USD 45.87M 4.34M Jun/2025
Almirall EUR 91.3M 55.52M Mar/2025
Amarin USD 36.57M 397K Mar/2025
Amgen USD 1.69B 4M Jun/2025
argenx SE USD 321.35M 45.11M Jun/2025
AstraZeneca USD 5.01B 1.42B Jun/2025
Bayer EUR 3.55B 162M Jun/2025
BioMarin Pharmaceutical USD 232.28M 26.16M Jun/2025
Demant DKK 5.95B 319M Jun/2025
Exelixis USD 134.86M 2.32M Jul/2025
Fresenius Medical Care EUR 792M 41M Jun/2025
Galapagos EUR 30.67M 13.12M Jun/2025
Genmab DKK 144M 18M Jun/2025
GlaxoSmithKline GBP 2.14B 80M Jun/2025
GN Store Nord DKK 1.42B 101M Jun/2025
GRIFOLS EUR 282.76M 41.9M Jun/2025
Hikma Pharmaceutical USD 288M 8M Dec/2024
Insmed USD 76.44M 71.11M Jun/2025
Merck EUR 1.48B 9M Jun/2025
Novartis USD 3.44B 384M Jun/2025
Regeneron Pharmaceuticals USD 634.2M 1.2M Jun/2025
Roche Holding CHF 3.61B 381M Dec/2024
Sanofi EUR 2.63B 408M Jun/2025
UCB EUR 1.29B 221M Dec/2024